» Articles » PMID: 19236938

Metabolic Characterization of a Hyper-productive State in an Antibody Producing NS0 Myeloma Cell Line

Overview
Journal Metab Eng
Date 2009 Feb 25
PMID 19236938
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Metabolic profiling or metabolomics is the analysis of a larger number of small metabolic compounds within cells. While this technique has been utilized to study microbial and yeast strains under different physiochemical conditions, very little has been reported regarding its application in mammalian cell culture. Here, the physiological and metabolic changes observed during the proliferation arrest of an antibody producing GS-NS0 mouse myeloma cell line were studied using conventional biochemical analysis and one-dimensional nuclear magnetic resonance (NMR)-based metabolic profiling. Proliferation-arrested cells had increased antibody productivity, enhanced normalized mitochondrial membrane potential, and showed changes in the consumption of several amino acids. Further investigation into these physiological changes was carried out by (1)H NMR profiling followed by principle component analysis (PCA). The resulting data showed a clear separation of the arrested and control spectra that related to the altered metabolic state of the arrested culture. Metabolites associated with phosphatidylcholine homeostasis, lipid and fatty acid metabolism, and ascorbate formation were found to be present in significant amount in these cultures. Taken together, the results suggested that there was a link between the metabolic alterations and the hyper-productive state, possibly relating to vesicle recycling and secretory functions, and mechanism to counteract against the generation of reactive oxygen species. While the use of metabolic profiling is still in its infancy, its potential to enhance the understanding of physiological processes in mammalian cell lines used for antibody production is certain.

Citing Articles

Metabolomics approach reveals key plasma biomarkers in multiple myeloma for diagnosis, staging, and prognosis.

Wang X, Cheng L, Liu A, Liu L, Gong L, Shen G J Transl Med. 2025; 23(1):163.

PMID: 39915820 PMC: 11800462. DOI: 10.1186/s12967-024-05848-7.


Metabolic Profiling of CHO Cells during the Production of Biotherapeutics.

Coulet M, Kepp O, Kroemer G, Basmaciogullari S Cells. 2022; 11(12).

PMID: 35741058 PMC: 9221972. DOI: 10.3390/cells11121929.


Diagnostic Value of H NMR-Based Metabolomics in Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, and Breast Cancer.

Morad H, Abou-Elzahab M, Aref S, El-Sokkary A ACS Omega. 2022; 7(9):8128-8140.

PMID: 35284729 PMC: 8908535. DOI: 10.1021/acsomega.2c00083.


11C-acetate positron emission tomography is more precise than 18F-fluorodeoxyglucose positron emission tomography in evaluating tumor burden and predicting disease risk of multiple myeloma.

Chen M, Zhu W, Du J, Yang C, Han B, Zhou D Sci Rep. 2021; 11(1):22188.

PMID: 34773054 PMC: 8590058. DOI: 10.1038/s41598-021-01740-2.


Positron Emission Tomography (PET) Radiopharmaceuticals in Multiple Myeloma.

Sachpekidis C, Goldschmidt H, Dimitrakopoulou-Strauss A Molecules. 2020; 25(1).

PMID: 31905752 PMC: 6982887. DOI: 10.3390/molecules25010134.